دورية أكاديمية
Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites?
| العنوان: | Immune checkpoint inhibitors plus chemotherapy in first-line endometrial cancer treatment: Still the era of microsatellites? |
|---|---|
| المؤلفون: | Maiorano MFP; Obstetrics and Gynaecology Unit, Department of Biomedical Sciences and Human Oncology, University of Bari 'Aldo Moro', Bari, Italy., Messina C; Oncology Unit, ARNAS Civico, Palermo, Italy., Maiello E; Oncology Unit, Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy., Cormio G; Gynaecologic Oncology Unit, IRCCS Istituto Tumori 'Giovanni Paolo II', Bari, Italy.; Department of Interdisciplinary Medicine (DIM), University of Bari, Bari, Italy., Maiorano BA; Oncology Unit, Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy. |
| المصدر: | BJOG : an international journal of obstetrics and gynaecology [BJOG] 2024 Jul; Vol. 131 (8), pp. 1157-1159. Date of Electronic Publication: 2024 Jan 02. |
| نوع المنشور: | Journal Article; Meta-Analysis |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100935741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-0528 (Electronic) Linking ISSN: 14700328 NLM ISO Abbreviation: BJOG Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Original Publication: Oxford [England] : Blackwell Science, [2000]- |
| مواضيع طبية MeSH: | Endometrial Neoplasms*/drug therapy , Endometrial Neoplasms*/genetics , Immune Checkpoint Inhibitors*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Randomized Controlled Trials as Topic* , Progression-Free Survival*, Humans ; Female |
| مستخلص: | Objective: The combination of immune checkpoint inhibitors (ICIs) plus chemotherapy is currently being tested as the first-line treatment of advanced endometrial. We aimed to evaluate the efficacy and safety of this combination. Design: We performed a meta-analysis of randomized clinical trials. Population and Setting: Patients with advanced endometrial carcinoma receiving ICIs plus chemotherapy in the experimental arm, compared with chemotherapy plus placebo in the control arm, were included. Methods and Outcomes: We evaluated the progression-free survival (PFS) as an efficacy outcome and the number and grades of adverse events (AEs) for safety. Hazard ratios (HR) for PFS and risk ratios (RR) for AEs, with 95% confidence intervals (CI), were calculated. Results: 1303 patients were treated in the included studies. Adding ICIs to chemotherapy significantly improved PFS in mismatch repair deficient (dMMR-HR 0.29; 95% CI, 0.20-0.42; p < 0.00001) and in mismatch repair proficient (pMMR-HR 0.64; 95% CI, 0.46-0.90; p = 0.01) patients. No difference emerged for all-grades AEs (RR 1.00; p = 0.98), but the risk of ≥G3 AEs was increased in the ICIs + chemotherapy group (RR 1.22; 95% CI, 1.11-1.34; p < 0.0001). Conclusions: Adding ICIs to chemotherapy significantly improves PFS in first-line endometrial cancer, regardless of MMR status. (© 2024 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.) |
| References: | Maiorano BA, Maiorano MFP, Cormio G, Maglione A, Lorusso D, Maiello E. How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. Front Oncol. 2022;12:844801. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388:2159–2170. Mirza MR, Chase DM, Slomovitz BM, DePont Christensen R, Novàk Z, Black D, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388:2145–2158. Raffone A, Travaglino A, Mascolo M, Carotenuto C, Guida M, Mollo A, et al. Histopathological characterization of ProMisE molecular groups of endometrial cancer. Gynecol Oncol. 2020;157:252–259. Evrard C, Alexandre J. Predictive and prognostic value of microsatellite instability in gynecologic cancer (endometrial and ovarian). Cancer. 2021;13:2434. |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240102 Date Completed: 20240603 Latest Revision: 20240604 |
| رمز التحديث: | 20240605 |
| DOI: | 10.1111/1471-0528.17749 |
| PMID: | 38164107 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1471-0528 |
|---|---|
| DOI: | 10.1111/1471-0528.17749 |